Should there be a standard therapy for mantle cell lymphoma?

Genomewide DNA methylation analysis reveals novel targets for drug development in mantle cell lymphoma

(2010) V. V. Leshchenko et al.   BLOOD

Phase 1 trial of bortezomib plus R-CHOP in previously untreated patients with aggressive non-Hodgkin lymphoma

(2010) Richard R. Furman et al.   CANCER

Genomic and Gene Expression Profiling Defines Indolent Forms of Mantle Cell Lymphoma

(2010) V. Fernandez et al.   CANCER RESEARCH

Phase I Dose Finding Studies of Obatoclax (GX15-070), a Small Molecule Pan-BCL-2 Family Antagonist, in Patients with Advanced Solid Tumors or Lymphoma

(2010) J. J. Hwang et al.   CLINICAL CANCER RESEARCH

Navitoclax, a targeted high-affinity inhibitor of BCL-2, in lymphoid malignancies: a phase 1 dose-escalation study of safety, pharmacokinetics, pharmacodynamics, and antitumour activity

(2010) Wyndham H Wilson et al.   LANCET ONCOLOGY

Synergistic antitumor effects of lenalidomide and rituximab on mantle cell lymphoma in vitro and in vivo

(2009) Liang Zhang et al.   AMERICAN JOURNAL OF HEMATOLOGY

Prognostic impact of proliferative index determined by quantitative image analysis and the International Prognostic Index in patients with mantle cell lymphoma

(2009) R. Schaffel et al.   ANNALS OF ONCOLOGY

T cells helping GVHD: take-away lessons

(2009) D. Fowler   BLOOD

Mature results of the M. D. Anderson Cancer Center risk-adapted transplantation strategy in mantle cell lymphoma

(2009) C. S. Tam et al.   BLOOD

Patients with chemotherapy-refractory mantle cell lymphoma experience high response rates and identical progression-free survivals compared with patients with relapsed disease following treatment with single agent bortezomib: results of a multicentre phase 2 clinical trial

(2009) Owen A. O’Connor et al.   BRITISH JOURNAL OF HAEMATOLOGY

Lenalidomide oral monotherapy produces a high response rate in patients with relapsed or refractory mantle cell lymphoma

(2009) Thomas M. Habermann et al.   BRITISH JOURNAL OF HAEMATOLOGY

Cladribine: not just another purine analogue?

(2009) Stephen Spurgeon et al.   EXPERT OPINION ON INVESTIGATIONAL DRUGS

Phase II Study of Yttrium-90–Ibritumomab Tiuxetan in Patients With Relapsed or Refractory Mantle Cell Lymphoma

(2009) Michael Wang et al.   JOURNAL OF CLINICAL ONCOLOGY

Immunochemotherapy and Autologous Stem-Cell Transplantation for Untreated Patients With Mantle-Cell Lymphoma: CALGB 59909

(2009) Lloyd E. Damon et al.   JOURNAL OF CLINICAL ONCOLOGY

Outcome of Deferred Initial Therapy in Mantle-Cell Lymphoma

(2009) Peter Martin et al.   JOURNAL OF CLINICAL ONCOLOGY

Coactivator function of RIP140 for NF B/RelA-dependent cytokine gene expression

(2008) I. Zschiedrich et al.   BLOOD

Long-term progression-free survival of mantle cell lymphoma after intensive front-line immunochemotherapy with in vivo-purged stem cell rescue: a nonrandomized phase 2 multicenter study by the Nordic Lymphoma Group

(2008) C. H. Geisler et al.   BLOOD

Phase II multicenter study of oblimersen sodium, a Bcl-2 antisense oligonucleotide, in combination with rituximab in patients with recurrent B-cell non-Hodgkin lymphoma

(2008) Barbara Pro et al.   BRITISH JOURNAL OF HAEMATOLOGY

The subcellular Sox11 distribution pattern identifies subsets of mantle cell lymphoma: correlation to overall survival

(2008) Xiao Wang et al.   BRITISH JOURNAL OF HAEMATOLOGY

Long‐term results of the treatment of patients with mantle cell lymphoma with cladribine (2‐CDA) alone (95‐80‐53) or 2‐CDA and rituximab (N0189) in the North Central Cancer Treatment Group

(2008) David J. Inwards et al.   CANCER

Lenalidomide Enhances Natural Killer Cell and Monocyte-Mediated Antibody-Dependent Cellular Cytotoxicity of Rituximab-Treated CD20+ Tumor Cells

(2008) L. Wu et al.   CLINICAL CANCER RESEARCH

Five-Gene Model to Predict Survival in Mantle-Cell Lymphoma Using Frozen or Formalin-Fixed, Paraffin-Embedded Tissue

(2008) Elena Hartmann et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase II Multicenter Study of Bendamustine Plus Rituximab in Patients With Relapsed Indolent B-Cell and Mantle Cell Non-Hodgkin's Lymphoma

(2008) K. Sue Robinson et al.   JOURNAL OF CLINICAL ONCOLOGY

Improvement of Overall Survival in Advanced Stage Mantle Cell Lymphoma

(2008) Annina Herrmann et al.   JOURNAL OF CLINICAL ONCOLOGY

A new prognostic index (MIPI) for patients with advanced-stage mantle cell lymphoma

(2007) E. Hoster et al.   BLOOD

Phase II Trial of a Transplantation Regimen of Yttrium-90 Ibritumomab Tiuxetan and High-Dose Chemotherapy in Patients With Non-Hodgkin's Lymphoma

(2007) Amrita Krishnan et al.   JOURNAL OF CLINICAL ONCOLOGY